http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-202022104280-U1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f097352f06e76751d7f6ee6676925931
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f4c5f78dcc4c922831b8a115d570178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ecf8b7884c2b35213bf29ed6b3e755b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5bc1530643883962ffc8c95d6d2e499
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92d55b1f01f549eac64f32ac15b14e7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_80cd2913b6b9a9844532c0d04b40be99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_642068a5a62f67d58b00a6f7bcb7c7b3
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
filingDate 2022-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2022-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber DE-202022104280-U1
titleOfInvention Fast-release solid oral celecoxib composition for the treatment of acute pain
abstract A simple, inexpensive pharmaceutical composition of celecoxib to improve its solubility, consisting of: a) celecoxib is 100 mg; b) PEG 400 is 140 to 150 mg; c) avicel ph 102 is 320 to 330 mg; d) Aerosil 200 is 105 to 110 mg; e) croscarmellose sodium is 15 to 40 mg; f) cross povidone is 15 to 40 mg; g) sodium starch glycolate is 15 to 40 mg; and wherein the percentage of drug release at the end of 60 minutes was 93.59%.
priorityDate 2022-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24261
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457707758
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2662
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6917
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506282
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527835

Total number of triples: 35.